Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities.,ACS Chemical Neuroscience

当前位置： X-MOL 学术 › ACS Chem. Neurosci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities.
ACS Chemical Neuroscience ( IF 4.1 ) Pub Date : 2018-09-17 , DOI: 10.1021/acschemneuro.8b00402
Wing-Yu Fu , Xiujiao Wang , Nancy Y Ip ₁

Affiliation

Alzheimer's disease is a progressive neurodegenerative disease, and its incidence is expected to increase owing to the aging population worldwide. Current therapies merely provide symptomatic relief. Therefore, interventions for AD that delay the disease onset or progression are urgently required. Recent genomics and functional studies suggest that immune/inflammatory pathways are involved in the pathogenesis of AD. Although many anti-inflammatory drug candidates have undergone clinical trials, most have failed. This might be because of our limited understanding of the pathological mechanisms of neuroinflammation in AD. However, recent advances in the understanding of immune/inflammatory pathways in AD and their regulatory mechanisms could open up new avenues for drug development targeting neuroinflammation. In this Review, we discuss the mechanisms and status of different anti-inflammatory drug candidates for AD that have undergone or are undergoing clinical trials and explore new opportunities for targeting neuroinflammation in AD drug development.

中文翻译：

针对神经炎症作为阿尔茨海默氏病的治疗策略：机制，候选药物和新机遇。

阿尔茨海默氏病是一种进行性神经退行性疾病，由于全世界人口的老龄化，其发病率预计会增加。当前的疗法仅提供症状缓解。因此，迫切需要对AD进行干预以延缓疾病的发作或发展。最近的基因组学和功能研究表明，免疫/炎症途径与AD的发病机制有关。尽管许多抗炎药候选者都经过了临床试验，但大多数都以失败告终。这可能是由于我们对AD神经炎症的病理机制了解有限。但是，AD免疫/炎症途径及其调控机制的最新进展可以为靶向神经炎症的药物开发开辟新途径。在这篇评论中，

更新日期：2018-09-17

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11